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OBJECTIVES: In this workshop, we will (1) lay out the
set of conditions for assessing the quality of models, (2)
provide examples from the Duke Stroke Policy Model of
how these conditions may be met, and (3) engage partici-
pants in a discussion of cases in other clinical areas.
PARTICIPANTS WHO WOULD BENEFIT: Those who
develop and use decision/cost-effectiveness models.
In an ideal world all clinical decisions would be based on
evidence from large comprehensive scientific studies. In
the complex world of actual practice—the world of phar-
macoeconomics—such evidence is often impractical or
impossible to obtain. Models are used to help decision-
makers make plausible and useful inferences in the ab-
sence of perfect information. Despite the broad applica-
tion of models in this context, the process and conclusions
of modeling exercises are frequently suspect. Concerns
include: (1) failure to use the best available data; (2) inac-
cessibility of the model code; (3) lack of validation; and
(4) difficulty interpreting the results of technical analyses.
Despite recommendations from the US Preventive Ser-
vices Task Force intended to address these concerns,
models are still held in low regard. As part of the Stroke
PORT project, a simulation model of stroke development
and outcomes was developed. This model has since been
expanded to accommodate a variety of potential inter-
ventions and data sources and is currently designated the
Duke Stroke Policy Model (DSPM). One of the major ob-
jectives of the DSPM has been to address the above con-
cerns. Our approach has been to (1) use the best data; (2)
vigorously promote an open-code public-use application,
available on the Internet; (3) perform rigorous validation;
and (4) develop user-friendly applications based on the
validated core code, tailored to different user groups. Re-
searchers, teachers and public health professionals are
encouraged to use the DSPM for academic and other non-
commercial applications, and to engage with the develop-
ers to promote the continuing improvement of the model.
In this workshop, we will (1) lay out the set of conditions
for assessing the quality of models, (2) provide examples
from the DSPM of how these conditions may be met, and
(3) engage participants in a discussion of cases in other
clinical areas.
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OBJECTIVES: Selection bias in observational studies is
described. Instrumental variable estimation is presented
in detail as a method of identification of treatment ef-
fects. Practical issues related to the proper implementa-
tion of this technique are stressed. Propensity score meth-
ods are also discussed.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who use, evaluate, or conduct observational studies.
While estimates of treatment outcomes and costs from
randomized clinical trials are still considered the gold
standard, the use of observational data for these esti-
mates is common. Observational data are less costly to
obtain, readily available, and represent actual practice.
However, there is always a danger of selection bias when
these data are used to identify the costs or outcomes of
one particular treatment versus another. This is true even
when quality risk adjustment methods and propensity
score methods are employed. Instrumental variable esti-
mation and propensity score methods have both been
proposed to overcome the selection bias problem in ob-
servational studies. We describe selection bias and how
instrumental variables analysis and propensity score
methods overcome the problem. We then explain how
one would apply these techniques correctly to common
research problems emphasizing the importance of choos-
ing when propensity score methods are sufficient or when
instrumental variables analysis should be used.
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OBJECTIVES: To provide a detailed overview of the reg-
istry concept and implementation, emphasizing its re-
search value as well as its potential role in support of new
product development and marketing and in the develop-
ment and testing of disease management programs.
PARTICIPANTS WHO WOULD BENEFIT: Persons
who have responsibility for planning or conducting out-
comes research or disease management programs in the
pharmaceutical industry, hospitals, or managed care.
There is growing enthusiasm for the use of health-care
claims data bases representing thousands or even millions
of covered lives to assess the potential value of medical
interventions, including pharmaceuticals and disease
management programs. However, evaluations of the ef-
fectiveness and safety of such interventions conducted in
this manner may be confounded by clinical or patient dif-
ferences between treatment groups that are not captured
in readily-available databases. Patient registries designed
to meet specific research objectives can provide a more
robust source of data for outcomes research and disease
management by linking administrative data bases, medi-
cal records, patient questionnaires, death certificates, etc.
The result is comprehensive longitudinal information on
diagnosis, treatment, course of illness, outcomes, quality
of life, and costs of the diseases of interest. By seeking the
informed consent of participants the registry can also ob-
viate growing public concerns about the research use of
confidential health-care data. Workshop participants will
